| In providing support for global psychiatric drug development programs, we bring customers a team with vast mental-health clinical research experience. We have access to leading academic and private practice investigative sites, whose specialty is evaluating, diagnosing and treating the psychiatric patient populations customers seek.
We've worked across all psychiatric indications including addiction, ADD/ADHD, Anxiety, Bipolar Disorder, Depression, Panic, Schizophrenia, and Smoking Cessation. We know many factors greatly influence the outcome of psychiatric clinical trials. Rater reliability, placebo response rates, study design and methodology, patient expectations and the quality of patient-physician interaction are all factors to consider. INC Research CNS addresses these important issues and provides expertise to facilitate discovery of safe and effective treatments for mental disorders. |
Case Studies
Pain: Chronic, Non-Malignant Pain
Pain: Chronic Painful Diabetic Neuropathy
Neurology: Stroke
Psychiatry: Panic Attacks
Psychiatry: Major Depressive Disorder
Leadership
Michael Gibertini, PhD
Executive Vice President, CNS
Thomas Schlagheck, PhD
Vice President, Clinical Development, Global Analgesia
Thomas Zoda, PhD
Senior Vice President, Clinical Development, Neurology and Psychiatry
Biljana Andjelkovic, MD
Vice President, Clinical Operations, Global Analgesia
Warren Prosser, MBA
Vice President, Clinical Operations Global Analgesia
Andrew Silverman, PhD
Vice President, Neurology
|
